SCHEMBL5787697

SCHEMBL5787697

CCOC(=O)[C@H](Cc1ccc(O)c(C(C)=O)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46
SCN9A Q15858 1/20 0.45
CTSS P25774 6/20 0.45
CTSK P43235 6/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
TACR1 P25103 1/20 0.44
CTSB P07858 2/20 0.44
ACE P12821 1/20 0.43
KLK5 Q9Y337 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27573951 1.00 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL5122384 0.91 KLK5 (0.51) CTSSCTSKCTSBACEKLK5
SCHEMBL5122389 0.91 KLK5 (0.51) CTSSCTSKCTSBACEKLK5
SCHEMBL14576986 0.89 LCK (0.52) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL8254848 0.89 LCK (0.52) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL14431256 0.88 ITGB3 (0.44) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL5206885 0.88 ITGB3 (0.44) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL7160906 0.85 CYP1A2 (0.48) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL3816383 0.85 CYP1A2 (0.48) ALDH1A1MAPTKDM4EGAAPKM
SCHEMBL5312623 0.85 CYP1A2 (0.49) ALDH1A1MAPTKDM4EGAAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1301964-C Inhibitors of alpha 4-mediated cell adhesion TANABE SEIYAKU CO (JP) 2007-02-28 CN disclosed
EP-1049662-B1 INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION TANABE SEIYAKU CO (JP) 2006-06-21 EP disclosed
US-6855843-B2 Inhibitors of α4 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2005-02-15 US disclosed
US-20030191118-A1 Inhibitors of alpha4 mediated cell adhesion TANABE SEIYAKU CO., LTD. 2003-10-09 US disclosed
US-6521666-B1 Inhibitors of α4 mediated cell adhesion TANABE SEIYAKU CO., LTD. (JP) 2003-02-18 US disclosed
CN-1288457-A Inhibitors of & alpha, 4 mediated cell adhesion TANABE SEIYAKU CO (JP) 2001-03-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191118-A1 Inhibitors of alpha4 mediated cell adhesion ITGB4, ITGA4, VCAM1 ALDH1A1 312/4885MAPT 4289/4885KDM4E 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.